Aarey Drugs & Pharmaceuticals Limited manufactures and supplies pharmaceutical formulations and related healthcare products. The company operates in the pharmaceutical sector with a focus on manufacturing and supplying medicines across therapeutic categories. Its business is influenced by domestic healthcare demand, product approvals, manufacturing capabilities, and relationships with pharmaceutical customers. Expansion of healthcare access and increasing pharmaceutical consumption provide a structural opportunity for the industry. Regulatory compliance, product quality, pricing, and competition remain important considerations.
| Market cap | Sales (TTM) | Net profit (TTM) | P/E | EPS (TTM) | P/B | ROE | ROE previous year | ROCE | Debt / equity | Free cash flow | EV / EBITDA | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹324 cr | ₹415 cr | ₹5 cr | 62.2 | 1.83 | 2.15 | 2.7% | 3.0% | 5.6% | 0.33 | ₹-2 cr | 27.9 | 1.31 |
| Quarter | Sales ₹ cr | Net profit ₹ cr | EPS | EPS YoY | Sales YoY | Net margin |
|---|---|---|---|---|---|---|
| Jun 2026 | 45 | 1 | 0.36 | -25.0% | -56.3% | 2.3% |
| Mar 2026 | 190 | 2 | 0.55 | +1275.0% | +75.3% | 0.8% |
| Dec 2025 | 96 | 1 | 0.20 | — | — | 1.3% |
| Sep 2025 | 84 | 1 | 0.72 | -36.8% | -20.0% | 1.2% |
| Jun 2025 | 102 | 1 | 0.48 | -45.5% | -19.5% | 1.3% |
| Mar 2025 | 108 | 0 | 0.04 | -94.8% | -48.6% | 0.4% |
| Sep 2024 | 105 | 2 | 1.14 | +267.7% | +81.8% | 1.5% |
| Jun 2024 | 127 | 1 | 0.88 | +203.4% | +149.1% | 1.0% |
| Check | Result |
|---|---|
| Latest quarter EPS up 25%+ on a year ago | ✗ Fail |
| EPS growth accelerating over 3 quarters | — Not assessable |
| Sales up 25%+, or sales growth accelerating | ✗ Fail |
| Annual EPS up 25%+ in each of the last 2 years | — Not assessable |
| Net margin above the same quarter last year | ✓ Pass |
| Method | Checks | Score | Verdict |
|---|---|---|---|
| Minervini | ✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✓ Close above the 50-day ✓ At least 25% above the 52-week low · low 50.75 ✓ Within 25% of the 52-week high · high 113.87 ✓ RS percentile 70 or more · RS 93 Trend template - the gate, measured: a modest 21-day edge. | 8/8 | Pass |
| Weinstein | Stan Weinstein's stage analysis on the 30-week moving average. | Stage 2 - advancing | |
| CAN SLIM | ✗ C latest quarter EPS up 25%+ — A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 113.87 ✓ S more volume on up days than down days (50 sessions) · 3.43x ✓ L RS percentile 80 or more · RS 93 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist. | 4/5 | Strong |
| Darvas | ✗ Box top confirmed (3 sessions below the new high) · top 113.50 — Box bottom confirmed (3 sessions holding) ✓ Close above the box top · close 113.87 ✗ Volume at least 1.5x its 50-day average · 0.9x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high. | 79/100 | Forming |
| Turtle | ✓ Close above the prior 55-session high · 113.50 ✓ Close above the prior 20-session high · 113.50 ✗ Close below the prior 20-session low · 97.24 Donchian channel breakout - the Turtle traders' entry. | Breakout (55-day) | |
| Greenblatt | — Earnings yield (EBITDA / EV) · 3.6% — Return on capital (ROCE) · 5.6% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately. | 8/100 | Weak |
| Graham | ✗ Price at or below the Graham number · Graham number 46.70 ✗ P/E 15 or less · P/E 62.2 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 2.15 ✗ Current ratio 2 or more · 1.81 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests. | 41/100 | Expensive |
| Piotroski | ✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✗ ROA rising ✓ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✗ Current ratio rising · 1.81 ✗ No new shares issued — Margin rising (net margin) — Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026. | 4/7 | Average |
| Stock | 1M % | 3M % | 6M % | 1Y % | 3Y % | 5Y % | P/E | P/B | ROE % | ROCE % | ROA % | D/E | EV/EBITDA | ₹ Cr | Sales TTM ₹ Cr | Profit TTM ₹ Cr | EPS | Beta |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AAREYDRUGS this stock | +11.5 | +49.8 | +34.1 | +29.5 | +158.8 | +222.1 | 62.2 | 2.15 | 2.7 | 5.6 | — | 0.33 | 27.9 | 324 | 415 | 5 | 1.8 | 1.31 |
| BLISSGVS | -8.0 | +29.9 | +147.2 | +312.3 | +606.5 | +476.9 | 48.7 | 5.57 | 11.5 | 16.8 | — | 0.00 | 29.3 | 6,650 | 1,005 | 142 | 12.9 | 1.10 |
| VENUSREM | +0.7 | -5.9 | +55.8 | +252.6 | +518.8 | +242.4 | 18.3 | 3.21 | 16.8 | 21.9 | — | 0.00 | 13.7 | 2,130 | 811 | 116 | 86.9 | 0.88 |
| INDSWFTLAB | -5.7 | +50.4 | +153.3 | +247.2 | +287.1 | +472.2 | 51.6 | 2.21 | 3.2 | 3.9 | — | 0.01 | 33.4 | 3,056 | 665 | 57 | 6.8 | 0.78 |
| MOREPENLAB | +0.5 | +108.6 | +194.2 | +152.6 | +242.7 | +132.7 | 47.5 | 5.34 | 7.9 | 10.1 | — | 0.16 | 40.2 | 6,657 | 1,951 | 140 | 2.6 | 1.46 |
| SHILPAMED | -14.2 | +40.1 | +113.1 | +146.1 | +421.3 | +189.7 | 57.3 | 6.61 | 9.8 | 11.4 | — | 0.25 | — | 17,130 | 1,682 | 297 | 15.3 | 0.87 |
| RUBICON | -15.1 | -1.7 | +60.3 | +140.3 | — | — | 83.8 | 19.08 | 22.4 | — | — | 0.20 | 61.3 | 24,587 | 1,936 | 288 | 17.7 | 0.34 |
| LAURUSLABS | +5.9 | +32.7 | +83.2 | +129.9 | +421.9 | +235.3 | 88.9 | 21.09 | 18.2 | 17.9 | — | 0.45 | 62.0 | 1.12L | 8,839 | 1,252 | 23.3 | 0.74 |
| ZIMLAB | +2.0 | +14.2 | +73.3 | +101.9 | +17.5 | — | 168.5 | 2.50 | 2.1 | 5.5 | — | 0.42 | 21.1 | 740 | 397 | 4 | 0.8 | 0.75 |
| ACUTAAS | -5.4 | -11.0 | +35.0 | +97.5 | — | — | 69.0 | 16.11 | 24.0 | 31.7 | — | 0.02 | 49.9 | 26,636 | 1,462 | 387 | 47.2 | 0.77 |
| IOLCP | -9.8 | +17.8 | +108.9 | +87.8 | +99.0 | +56.2 | 32.0 | 2.99 | 7.9 | 10.7 | — | 0.07 | 20.7 | 5,376 | 2,524 | 168 | 5.7 | 1.13 |